眼疗公司：药物获胜，股票下跌，而这正是机会
· seekingalpha.com
眼疗公司的AXPAXLI在3期SOL-1试验中表现强劲，为明确的监管路径提供支持，预计第四季度提交新药申请。了解为何我将OCUL股票评为买入。
Ocular Therapeutix ( OCUL ) closed at $6.61 on Thursday, close to its 52-week low of $6.00 and well below the $16.44 high. For a company that reported one of th...